Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Dinardo, CD
• Schuh, AC
• Stein, EM
• Wei, A
• De Botton, S
• Zeidan, AM
• Fathi, AT
• Quek, L
• Kantarjian, HM
• Frattini, MG
• Lersch, F
• Gong, J
• Franovic, A
• Vyas, P
• Dohner, H

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible